1
|
van 't Erve I, Punt CJA, Meijer GA, Fijneman RJA. Reply to R. Pham et al. JCO Precis Oncol 2022; 6:e2200053. [PMID: 35344447 DOI: 10.1200/po.22.00053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Iris van 't Erve
- Iris van 't Erve, MSc, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Cornelis J.A. Punt, MD, PhD, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; and Gerrit A. Meijer, MD, PhD, and Remond J.A. Fijneman, PhD, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Cornelis J A Punt
- Iris van 't Erve, MSc, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Cornelis J.A. Punt, MD, PhD, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; and Gerrit A. Meijer, MD, PhD, and Remond J.A. Fijneman, PhD, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Gerrit A Meijer
- Iris van 't Erve, MSc, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Cornelis J.A. Punt, MD, PhD, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; and Gerrit A. Meijer, MD, PhD, and Remond J.A. Fijneman, PhD, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Remond J A Fijneman
- Iris van 't Erve, MSc, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Cornelis J.A. Punt, MD, PhD, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; and Gerrit A. Meijer, MD, PhD, and Remond J.A. Fijneman, PhD, Department of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| |
Collapse
|
2
|
Tizek L, Schuster B, Gebhardt C, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N. Molekulardiagnostik in der Dermatologie: Eine Online-Umfrage zur Untersuchung von Nutzung, Hürden und Anforderungen in Deutschland. J Dtsch Dermatol Ges 2022; 20:287-296. [PMID: 35304958 DOI: 10.1111/ddg.14659_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 09/20/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Linda Tizek
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland
| | - Barbara Schuster
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| | - Christoffer Gebhardt
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland
| | - Kristian Reich
- Competenzzentrum Translationale Forschung bei entzündlichen Hauterkrankungen, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland
| | - Ralph von Kiedrowski
- Dermatologische Praxis und dermatologisches Studienzentrum (CMS3), Dr. Ralph von Kiedrowski, Selters/Westerwald, Deutschland
| | - Tilo Biedermann
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland
| | - Kilian Eyerich
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| | - Alexander Zink
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| | - Natalie Garzorz-Stark
- Technische Universität München, Medizinische Fakultät, Klinik und Poliklinik für Dermatologie und Allergologie, München, Deutschland.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Schweden
| |
Collapse
|
3
|
Tizek L, Schuster B, Gebhardt C, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N. Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany. J Dtsch Dermatol Ges 2021; 20:287-295. [PMID: 34962069 DOI: 10.1111/ddg.14659] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 09/20/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND OBJECTIVES Molecular diagnostics (MDx) increasingly gains importance in dermatology and its application is a prerequisite for personalized medicine. The goal of this cross-sectional study was to determine how MDx is implemented in dermatologists' offices in the three fields of oncology, inflammation and infectiology and which hurdles office-based dermatologists face in terms of MDx. METHODS Physician members of the Association of the German Dermatologists (Berufsverband der Deutschen Dermatologen e. V.; BVDD) were surveyed via an online questionnaire on MDx. RESULTS 39.6 % of the 192 participants reported using MDx. Of these, the vast majority used MDx for diagnosing infectious diseases (86.5 % and 44.3 % of users perform MDx for detection of funghi and sexually transmitted diseases, respectively). Only a small minority applied MDx to answer oncological or immunological questions. The major obstacles for non-users as compared to users were difficulties in implementation, lack of expertise as well as time, personnel, and technical availability. Reimbursement was a main issue in both groups. CONCLUSIONS Despite availability of specific therapies requiring precision medicine, MDx has not yet been broadly implemented in office-based dermatology. To advance MDx, more needs to be done in terms of continuous education, availability of reliable and valid tests, and reimbursability.
Collapse
Affiliation(s)
- Linda Tizek
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany
| | - Barbara Schuster
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| | - Christoffer Gebhardt
- Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
| | - Kristian Reich
- Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Ralph von Kiedrowski
- Dermatology Office and Dermatology Study Center (CMS3) Dr. Ralph von Kiedrowski, Selters/Westerwald, Germany
| | - Tilo Biedermann
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany
| | - Kilian Eyerich
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| | - Alexander Zink
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| | - Natalie Garzorz-Stark
- Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany.,Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
4
|
Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions. Pathol Oncol Res 2020; 26:2469-2473. [PMID: 32572821 DOI: 10.1007/s12253-020-00818-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 04/23/2020] [Accepted: 05/06/2020] [Indexed: 12/14/2022]
Abstract
In some situations, there is a need for rapid mutation tests for guiding clinical decisions and starting targeted therapies with minimal delays. In this study we evaluated the turnaround time before and after the implementation of a fully automated multiplex assay for KRAS and NRAS/BRAF mutation tests (Idylla™ platform, Biocartis) in metastatic colorectal cancer. The objective of this project was to compare the turnaround times in 2017-2018 with the fully automated multiplex assay to the 2016 results with previous methods. Centers with a number of tests for metastatic colorectal cancer > 100 yearly and a usual turnaround time ≥ 3 weeks for mutation detection were selected. Results of 505 KRAS tests and 369 NRAS/BRAF tests were transmitted by 10 centers. The mean turnaround time from test prescription to reception of results was reduced from 25.8 days in 2016 to 4.5 days in 2017-2018. In conclusion, this pilot project shows that the Idylla™ platform for testing KRAS and NRAS/BRAF mutations allows an optimized turnaround time from test prescription to reception of results.
Collapse
|
5
|
Wong SQ, Scott R, Fox SB. KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. COLORECTAL CANCER 2016. [DOI: 10.2217/crc-2015-0009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Somatic mutations in the KRAS gene often occur in colorectal cancer (CRC) and are predictive for poor response to EGFR blockade therapy. Over the past decade, routine detection of KRAS mutations has been employed in many diagnostic centers using a range of methodological approaches including Sanger sequencing, pyrosequencing, high-resolution melt analysis and more recently, next-generation sequencing approaches. This article highlights the clinical relevance of KRAS-mutated CRCs, examines advantages and disadvantages of various detection methods and highlights the considerations that are critical for an accurate, rapid and efficient workflow to detect KRAS and other RAS mutations in CRC presently and in the future.
Collapse
Affiliation(s)
- Stephen Q Wong
- Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
| | - Rodney Scott
- Discipline of Medical Genetics & Centre for Information-Based Medicine, The University of Newcastle & Hunter Medical Research Institute, Newcastle, Australia
- Division of Genetics, Hunter Area Pathology Service, Newcastle, Australia
| | - Stephen B Fox
- Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
- Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
| |
Collapse
|